SG10201811584RA - Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof - Google Patents

Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof

Info

Publication number
SG10201811584RA
SG10201811584RA SG10201811584RA SG10201811584RA SG10201811584RA SG 10201811584R A SG10201811584R A SG 10201811584RA SG 10201811584R A SG10201811584R A SG 10201811584RA SG 10201811584R A SG10201811584R A SG 10201811584RA SG 10201811584R A SG10201811584R A SG 10201811584RA
Authority
SG
Singapore
Prior art keywords
nmda receptor
secondary structure
receptor modulators
structure stabilized
compounds
Prior art date
Application number
SG10201811584RA
Inventor
Joseph Moskal
Amin Khan
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of SG10201811584RA publication Critical patent/SG10201811584RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

SECONDARY STRUCTURE STABILIZED NMDA RECEPTOR MODULATORS AND USES THEREOF Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. No suitable figure
SG10201811584RA 2010-02-11 2011-02-11 Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof SG10201811584RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30347210P 2010-02-11 2010-02-11

Publications (1)

Publication Number Publication Date
SG10201811584RA true SG10201811584RA (en) 2019-01-30

Family

ID=44368160

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201501050RA SG10201501050RA (en) 2010-02-11 2011-02-11 Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
SG2012059358A SG183265A1 (en) 2010-02-11 2011-02-11 Secondary structure stabilized nmda receptor modulators and uses thereof
SG10201811584RA SG10201811584RA (en) 2010-02-11 2011-02-11 Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201501050RA SG10201501050RA (en) 2010-02-11 2011-02-11 Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
SG2012059358A SG183265A1 (en) 2010-02-11 2011-02-11 Secondary structure stabilized nmda receptor modulators and uses thereof

Country Status (13)

Country Link
US (2) US9101612B2 (en)
EP (1) EP2542254B1 (en)
JP (4) JP5928828B2 (en)
CN (2) CN105037492A (en)
AU (1) AU2011215704B2 (en)
BR (1) BR112012020142A2 (en)
CA (1) CA2789331C (en)
ES (1) ES2706063T3 (en)
IL (1) IL221400A (en)
MX (1) MX2012009388A (en)
RU (1) RU2566821C2 (en)
SG (3) SG10201501050RA (en)
WO (1) WO2011100585A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102186883B (en) 2008-09-18 2016-08-03 西北大学 Nmda receptor regulator and its purposes
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US9101612B2 (en) 2010-02-11 2015-08-11 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
KR101692275B1 (en) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 Secondary structure stabilized nmda receptor modulators and uses thereof
JP2016506961A (en) 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. Spirolactam NMDA receptor modulator and use thereof
AU2014212501A1 (en) 2013-01-29 2015-07-30 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US9828384B2 (en) * 2013-01-29 2017-11-28 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
EP3514158B1 (en) 2013-01-29 2022-10-12 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
KR20150110787A (en) * 2013-01-29 2015-10-02 노렉스, 인크. Spiro-lactam nmda receptor modulators and uses thereof
CN105764522A (en) * 2013-10-28 2016-07-13 诺雷克斯股份有限公司 NMDA receptor modulators and prodrugs, salts, and uses thereof
WO2015164859A1 (en) * 2014-04-25 2015-10-29 Naurex, Inc. Stable compositions of neuroactive peptides
JP6688748B2 (en) * 2014-06-23 2020-04-28 ノースウェスタン ユニバーシティ How to treat or ameliorate migraine
EP3916003A1 (en) * 2014-07-24 2021-12-01 Naurex, Inc. N-methyl-d-aspartate receptor modulators and methods of making and using same
KR20180064507A (en) 2015-10-14 2018-06-14 브리스톨-마이어스 스큅 컴퍼니 Selective NR2B antagonist
AU2016340237A1 (en) 2015-10-14 2018-05-31 Bristol-Myers Squibb Company Selective NR2B antagonists
CA3002070A1 (en) * 2015-10-16 2017-04-20 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
CA3013329A1 (en) * 2016-02-01 2017-08-10 M. Amin Khan Processes for synthesis of dipyrrolidine peptide compounds
EA201892657A1 (en) 2016-05-19 2019-05-31 Аптиникс Инк. SPYROLACTAM MODULATORS OF THE NMDA-RECEPTOR AND THEIR APPLICATION
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3490993B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof
EP3490974B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof
CA3031563C (en) 2016-08-01 2023-12-05 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
JP2019527233A (en) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド Spiro-lactam NMDA receptor modulator and use thereof
KR102462288B1 (en) 2016-08-01 2022-11-01 앱티닉스 인크. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
CN112218866A (en) * 2018-01-31 2021-01-12 阿普廷伊克斯股份有限公司 Spiro-lactam NMDA receptor modulators and uses thereof
CA3089561A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN110003309B (en) * 2019-04-09 2021-09-10 北京广为医药科技有限公司 Compounds that modulate NMDA receptor activity, pharmaceutical compositions and uses thereof
US20220273629A1 (en) * 2019-08-01 2022-09-01 Aptinyx Inc. Methods of treating disorders associated with elevated levels of antibodies that interact with the nmda receptor
CN114957445B (en) * 2022-05-31 2023-09-19 陕西脉元生物科技有限公司 NMDAR NR1 subunit, mutant of NMDAR, construction method and application thereof
CN114957444B (en) * 2022-05-31 2023-09-19 陕西脉元生物科技有限公司 NR1 subunit deletion mutant of NMDAR, mutant cell, construction method and application

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683221A (en) 1986-01-09 1987-07-28 Scripps Clinic And Research Foundation Lymphocyte-activating polypeptides
CA1305177C (en) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
CA2058975C (en) 1990-10-30 2000-06-06 Shuichi Kasai Antiinflammatory gel preparation
JP3318622B2 (en) 1992-05-27 2002-08-26 独立行政法人産業技術総合研究所 Prolyl endopeptidase inhibitor
FR2692268B1 (en) 1992-06-15 1994-08-19 Rhone Poulenc Rorer Sa New polypeptides having NMDA receptor activity, nucleic acids encoding these polypeptides and uses.
SE9301667D0 (en) 1993-05-14 1993-05-14 Kabi Pharmacia Ab NEW USE
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
TR199802537T2 (en) 1996-06-07 1999-03-22 Zeneca Limited Peptide tèrevleri.
WO1998005782A1 (en) 1996-08-02 1998-02-12 Zymogenetics, Inc. Testis-specific insulin homolog polypeptides
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
JP3955345B2 (en) 1996-09-27 2007-08-08 サントリー株式会社 New amino acid Daiji Harvein
US6897028B1 (en) 1997-07-07 2005-05-24 Florida State University Identification of molecular targets
WO1999002733A1 (en) * 1997-07-07 1999-01-21 Florida State University Identification of molecular targets
WO1999024584A1 (en) 1997-11-12 1999-05-20 Neurotherapeutics Methods for the detection and treatment of disease using a glycosyltransferase
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6274314B1 (en) 1998-04-02 2001-08-14 Nyxis Neurotherapies, Inc. Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
US6197820B1 (en) 1998-04-06 2001-03-06 Uab Research Foundation Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
US6025471A (en) 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
US6902886B1 (en) 1998-11-06 2005-06-07 The Research Foundation Of State University Of New York Genetic assay for protein nuclear transport
WO2000028090A2 (en) 1998-11-12 2000-05-18 Nyxis, Inc. Diagnostic assay for cancer
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
WO2001036685A2 (en) 1999-11-17 2001-05-25 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
WO2001057240A2 (en) 2000-02-01 2001-08-09 Agy Therapeutics, Inc. Interaction of nmda receptor with protein tyrosine phosphatase
WO2001096606A2 (en) 2000-06-14 2001-12-20 Nyxis Neurotherapies, Inc. Identification of genes and compounds for treatment of cancer
AU2001271366A1 (en) 2000-06-22 2002-01-02 Nyxis Neurotherapies, Inc. Neuroactive peptides for treatment of hypoxia and related conditions
EP1186303A3 (en) 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
AU2002236608A1 (en) 2000-12-14 2002-06-24 Nyxis Neurotherapies, Inc. High throughput assay to detect inhibitors of the map kinase pathway
WO2002072005A2 (en) 2001-03-07 2002-09-19 University Of Utah Research Foundation Linear y-carboxyglutamate rich conotoxins
AU2002255705A1 (en) 2001-03-12 2002-09-24 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
US7863304B2 (en) 2001-05-24 2011-01-04 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
CA2449168A1 (en) 2001-05-31 2002-12-05 The Trustees Of Princeton University Iap binding peptides and assays for identifying compounds that bind iap
WO2003010540A1 (en) 2001-07-25 2003-02-06 Nyxis Neurotherapies, Inc. Method of identifying nmda-related agent
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US7544478B2 (en) 2003-08-08 2009-06-09 The Burnham Institute Method for screening for compounds that modulate P16 mediated regulation of NMDA receptors
US7662856B2 (en) 2003-08-29 2010-02-16 The University Of Houston System Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US7951912B2 (en) 2005-08-26 2011-05-31 Wisconsin Alumni Research Foundation Poly-β-peptides from functionalized β-lactam monomers and antibacterial compositions containing same
WO2007027559A2 (en) * 2005-08-29 2007-03-08 Shashoua Victor E Neuroprotective and neurorestorative methods and compositions
WO2007103719A2 (en) 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
JP2010503677A (en) 2006-09-15 2010-02-04 シェーリング コーポレイション Azetidinone derivatives for treating disorders of lipid metabolism
CN101066945B (en) 2007-05-25 2010-05-19 中国科学院上海有机化学研究所 Process of synthesizing 3-substituted lactan compound
CN101125817B (en) 2007-08-03 2011-09-14 中国科学院上海有机化学研究所 Method for synthesizing aldehyde substituted small ring amines compounds with high enantioselectivity and 3-substituted lactams compounds with optical activity
WO2009039390A2 (en) 2007-09-20 2009-03-26 Naurex Inc. The development of glycobiology-based therapeutics for the treatment of brain tumors
JP5728752B2 (en) 2008-08-07 2015-06-03 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Process for producing macrocyclic compounds
CN102186883B (en) 2008-09-18 2016-08-03 西北大学 Nmda receptor regulator and its purposes
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
TW201028171A (en) 2008-12-15 2010-08-01 Calpis Co Ltd Peptides for inhibiting skin aging
WO2011003064A2 (en) 2009-07-02 2011-01-06 Naurex, Inc. Methods of treating neuropathic pain
PT2485751E (en) 2009-10-05 2014-09-01 Univ Northwestern Glyx-13 for use in a method of treating refractory depression
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
MX336774B (en) * 2009-12-17 2016-01-28 Merck Sharp & Dohme Quinoline amide m1 receptor positive allosteric modulators.
KR101692275B1 (en) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 Secondary structure stabilized nmda receptor modulators and uses thereof
US9101612B2 (en) * 2010-02-11 2015-08-11 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
KR20190037359A (en) 2011-04-27 2019-04-05 노오쓰웨스턴 유니버시티 Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
US8795919B2 (en) 2011-11-29 2014-08-05 Societe BIC & Sanyo Electric Co., Ltd. Fuel cell layer

Also Published As

Publication number Publication date
EP2542254A1 (en) 2013-01-09
MX2012009388A (en) 2012-10-01
AU2011215704B2 (en) 2015-07-23
SG183265A1 (en) 2012-09-27
RU2012138710A (en) 2014-03-20
CA2789331A1 (en) 2011-08-18
US9593145B2 (en) 2017-03-14
EP2542254A4 (en) 2013-07-10
US20130053325A1 (en) 2013-02-28
CN102933226A (en) 2013-02-13
AU2011215704A1 (en) 2012-08-30
SG10201501050RA (en) 2015-04-29
JP5928828B2 (en) 2016-06-01
IL221400A (en) 2016-07-31
IL221400A0 (en) 2012-10-31
JP2016185948A (en) 2016-10-27
ES2706063T3 (en) 2019-03-27
CN105037492A (en) 2015-11-11
JP2018119004A (en) 2018-08-02
JP2020117510A (en) 2020-08-06
EP2542254B1 (en) 2018-09-26
CA2789331C (en) 2017-11-07
JP6328169B2 (en) 2018-05-23
WO2011100585A1 (en) 2011-08-18
RU2566821C2 (en) 2015-10-27
BR112012020142A2 (en) 2020-08-18
US20160115197A1 (en) 2016-04-28
US9101612B2 (en) 2015-08-11
JP2013519683A (en) 2013-05-30

Similar Documents

Publication Publication Date Title
SG10201811584RA (en) Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
WO2013063120A3 (en) Nmda receptor modulators and uses thereof
PH12020550450A1 (en) Certain chemical entities, compositions and methods
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2013003309A (en) Substituted benzamide compounds.
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2011007930A (en) Crystalline insulin-conjugates.
IN2012DN02469A (en)
EP2571357A4 (en) Chemical compounds, compositions and methods for kinase modulation
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (en) Compounds and compositions as modulators of gpr119 activity
EP2651496A4 (en) Devices, systems and methods for the treatment of medical disorders
IL204785A0 (en) Systems and methods for treatment of medical conditions related to the central nervous system and for enhancing cognitive functions
IN2012DN01961A (en)
MX2013006595A (en) Treatment of spinal cord injury and traumatic brain injury using placental stem cells.
MX2012004078A (en) Compounds and compositions as modulators of gpr119 activity.
IN2014CN04014A (en)
MX2009006812A (en) Modulators of c3a receptor and methods of use thereof.
WO2012098281A3 (en) Trp-receptor-modulating peptides and uses thereof
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
MX342119B (en) Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators.
MX2010001187A (en) Modulators of ccr9 receptor and methods of use thereof.
WO2011014520A3 (en) Compounds and compositions as modulators of gpr119 activity